Cancer BiologyHaematologicaPeer-reviewed
IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia
Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh…·Mascha Binder
This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.
1 citation